newsfilter
← Latest News
GlobeNewswire·

Applied Molecular Transport Completes Enrollment of Phase 2 LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the company has completed enrollment of the Phase 2 LOMBARD trial for AMT-